Today, Blueberry announces a significant growth in its analytical capabilities with the investment in a new triple quadrupole mass spectrometry – the Agilent Ultivo LC/MS system. This instrument offers the ability to perform high quality quantitative analyses in support of all of our research programmes. Dr Heather Davies-Strickleton, Senior Analytical Scientist, says “Having the ability to quantify drug levels in our experiments is critical to developing new medicines in treating a range of topical diseases. With this investment we’ve significantly increased our in-house capability to analyse such samples and support the preclinical development of our new nanomedicines”.